Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patients own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.
November 9, 2022
RegMed Investors’ (RMi) closing bell: down sliding markets and sector responds to incomplete election results
November 9, 2022
RegMed Investors’ (RMi) pre-open: stock futures trade lower as election results are tallied
November 8, 2022
RegMed Investors’ (RMi) closing bell: after five (5) down sessions, it was inevitable that the algorithms would “rule”
November 8, 2022
RegMed Investors’ (RMi) pre-open: vote your conscious and your portfolio
November 7, 2022
RegMed Investors’ (RMi) closing bell: election and economics will determine the week as negative momentum moves the sector today
November 7, 2022
RegMed Investors’ (RMi) pre-open: the cell and gene therapy sector is stuck in earnings LPS (loss-per-share) season
November 4, 2022
RegMed Investors’ (RMi) closing bell: strolling a crooked session (10 of 35 covered companies stumbled)
November 4, 2022
RegMed Investors’ (RMi) pre-open: We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies
November 3, 2022
RegMed Investors’ (RMi) closing bell: taking it in the shins as sector trips
November 3, 2022
RegMed Investors’ (RMi) pre-open: gains followed by pain; so, what’s on-tap - earnings
35 companies, 1 interpreter!
Insight, foresight and recommendation
Vericel (VCEL) – Opened 1/2/18 at $5.90, saw a high of $7.30; started February at $8.15 slipping with a low of $6.60 and started March at $8.05 jumping to $11.35 on $3/6 after announcing a $300 K net incomeand a per share value of +$0.01. Further thoughts rflect strong use of an ATM and at this "peak" - a financing "could" ensue ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.